Career history of Michael Alfieri
Former positions of Michael Alfieri
| Companies | Position | Start | End |
|---|---|---|---|
| RADIUS HEALTH, INC. | Corporate Officer/Principal | 2016-12-31 | 2018-04-30 |
| MERRIMACK PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 2014-06-30 | 2016-12-31 |
| ANIKA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 2010-08-31 | 2014-06-30 |
| GENOCEA BIOSCIENCES, INC. | Comptroller/Controller/Auditor | 2018-06-20 | - |
| Director of Finance/CFO | 2018-06-20 | 2019-03-04 | |
| Corporate Officer/Principal | 2018-04-30 | 2018-06-20 |
Training of Michael Alfieri
| Bentley University | Graduate Degree |
Statistics
International
| United States | 6 |
Operational
| Comptroller/Controller/Auditor | 3 |
| Corporate Officer/Principal | 2 |
| Director of Finance/CFO | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| ANIKA THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Michael Alfieri
- Experience
